SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2018 Jul 25

PMID 30039249

Citations 39

Authors

John Wilding

Kevin Fernando

Nicola Milne

Marc Evans

Amar Ali

Steve Bain

Debbie Hicks

June James

Philip Newland-Jones

Dipesh Patel

Adie Viljoen

Affiliations

Soon will be listed here.

Abstract

Funding: Napp Pharmaceuticals Limited.

Citing Articles

Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway.

Zhang J, Chen X, Lv S, Hao Q PLoS One. 2025; 20(1):e0317295.

PMID: 39874368 PMC: 11774390. DOI: 10.1371/journal.pone.0317295.

The Bidirectional Relationship Between Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.

Williams D, Ali J, Cragg J, Chng C, Williams N, Stephens J Cureus. 2025; 16(12):e75993.

PMID: 39835079 PMC: 11743228. DOI: 10.7759/cureus.75993.

Dapagliflozin Suppresses High Glucose-Induced Proliferation, Oxidative Stress, and Fibrosis by Reducing Mettl3-Induced m6A Modification in Marcks mRNA.

Shi B, Wang J, Zhang J, Li J, Hao Y, Lin X Cardiovasc Toxicol. 2024; 25(1):110-120.

PMID: 39560681 DOI: 10.1007/s12012-024-09945-3.

Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus.

Gorgojo-Martinez J, Gorriz J, Cebrian-Cuenca A, Castro Conde A, Velasco Arribas M J Clin Med. 2024; 13(21).

PMID: 39518647 PMC: 11546491. DOI: 10.3390/jcm13216509.

SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

Borrego M, Lu Y, Reyes-Cosmelli F, Park Y, Yamashita T, Chiu J Breast Cancer Res Treat. 2024; 208(1):111-121.

PMID: 39177931 PMC: 11452482. DOI: 10.1007/s10549-024-07405-8.

References

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S . Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014; 103(3):373-81. DOI: 10.1016/j.diabres.2013.12.052. View

Grundy S, Benjamin I, Burke G, Chait A, Eckel R, Howard B . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100(10):1134-46. DOI: 10.1161/01.cir.100.10.1134. View

Watts N, Bilezikian J, Usiskin K, Edwards R, Desai M, Law G . Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2015; 101(1):157-66. PMC: 4701850. DOI: 10.1210/jc.2015-3167. View

Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H . Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016; 19(3):348-355. DOI: 10.1111/dom.12825. View

Neal B, Perkovic V, Mahaffey K, Fulcher G, Erondu N, Desai M . Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017; 19(7):926-935. PMC: 5485085. DOI: 10.1111/dom.12924. View

Raz I, Mosenzon O, Bonaca M, Cahn A, Kato E, Silverman M . DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018; 20(5):1102-1110. DOI: 10.1111/dom.13217. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Kosiborod M, Birkeland K, Cavender M, Fu A, Wilding J, Khunti K . Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab. 2018; 20(8):1983-1987. PMC: 6055705. DOI: 10.1111/dom.13299. View

Neeland I, McGuire D, Chilton R, Crowe S, Lund S, Woerle H . Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016; 13(2):119-26. PMC: 4768401. DOI: 10.1177/1479164115616901. View

10.

Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W, Meininger G . Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016; 128(4):371-80. DOI: 10.1080/00325481.2016.1169894. View

11.

Jardine M, Mahaffey K, Neal B, Agarwal R, Bakris G, Brenner B . The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017; 46(6):462-472. PMC: 5804835. DOI: 10.1159/000484633. View

12.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin J, Wanner C . Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2017; 39(5):363-370. DOI: 10.1093/eurheartj/ehx511. View

13.

Fadini G, Avogaro A . SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017; 5(9):680-681. DOI: 10.1016/S2213-8587(17)30257-7. View

14.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

15.

Zheng S, Roddick A, Aghar-Jaffar R, Shun-Shin M, Francis D, Oliver N . Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018; 319(15):1580-1591. PMC: 5933330. DOI: 10.1001/jama.2018.3024. View

16.

Khouri C, Cracowski J, Roustit M . SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. Diabetes Obes Metab. 2018; 20(6):1531-1534. DOI: 10.1111/dom.13255. View

17.

Gadzhanova S, Pratt N, Roughead E . Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract. 2017; 130:180-185. DOI: 10.1016/j.diabres.2017.06.018. View

18.

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View

19.

Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

20.

Wilding J . The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014; 68(6):682-91. PMC: 4238418. DOI: 10.1111/ijcp.12384. View